Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
Open Access
- 8 April 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (4) , e93909
Abstract
Rifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP). To detect the impact of rifaximin on the occurrence and characteristics of SBP. We prospectively studied all hospitalized patients that underwent a diagnostic paracentesis in our department from March 2012 to April 2013 for SBP and recorded all clinical data including type of SBP prophylaxis, prior use of rifaximin, concomitant complications of cirrhosis, as well as laboratory results and bacteriological findings. Patients were divided into the following three groups: no antibiotic prophylaxis, prophylaxis with rifaximin or with systemically absorbed antibiotic prophylaxis. Our study cohort comprised 152 patients with advanced liver cirrhosis, 32 of whom developed SBP during the study period. As expected, our study groups differed regarding a history of hepatic encephalopathy and SBP before inclusion into the study. None of the 17 patients on systemic antibiotic prophylaxis developed SBP while 8/27 patients on rifaximin and 24/108 without prophylaxis had SBP (p = 0.02 and p = 0.04 versus systemic antibiotics, respectively). In general, episodes of SBP were similar for patients treated with rifaximin and those without any prophylaxis. However, Escherichia coli and enterococci were dominant in the ascites of patients without any prophylaxis, while mostly klebsiella species were recovered from the ascites samples in the rifaximin group. Rifaximin pretreatment did not lead to a reduction of SBP occurrence in hospitalized patients with advanced liver disease. However, the bacterial species causing SBP were changed by rifaximin.Keywords
This publication has 39 references indexed in Scilit:
- Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal HypertensionPLOS ONE, 2013
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic EncephalopathyPLOS ONE, 2013
- Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB , and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux PumpsAntimicrobial Agents and Chemotherapy, 2013
- Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in miceJournal of Hepatology, 2012
- Bacterial infections other than spontaneous bacterial peritonitis in cirrhosisWorld Journal of Hepatology, 2012
- The Human Oral MicrobiomeJournal of Bacteriology, 2010
- Severe sepsis in cirrhosis†Hepatology, 2009
- Pathogenetic mechanisms of hepatic encephalopathyGut, 2008
- Liver cirrhosisThe Lancet, 2008
- Hepatic encephalopathyAmerican Journal of Gastroenterology, 2001